What Happened at the July Peptide PCAC Meeting and What's Next?
FDA PCAC meeting recommends 6 of 7 peptides reviewed but a formal review is still required for 503A compounding.
UPDATED July 28, 2026 On July 23-24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) met at the agency's White Oak Campus in Silver Spring, Maryland, to review seven peptides for possible addition to the 503A Bulk Substances List. Over the two days, the committee recommended six of the seven for 503A compounding.
This is not a green light. A PCAC recommendation is one step in a longer process, and formal FDA rulemaking is still required before any of these peptides can be legally compounded.
How the meeting came about: In 2023, the FDA placed 19 peptides and peptide-related bulk drug substances into Category 2, citing patient-safety concerns and insufficient human data. In February 2026, the HHS Secretary announced plans to expand lawful peptide access. In April 2026, the FDA removed 12 peptides from Category 2 and scheduled the July public review.
Here's a quick timeline of the events:
What Is the PCAC Meeting?
The Pharmacy Compounding Advisory Committee is a federal advisory committee that provides independent expert, technical, and scientific recommendations to the FDA Commissioner on drug compounding issues under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.
At the July meeting, the committee evaluated whether seven peptides should be added to the 503A Bulk Substances List, the list that governs which bulk drug substances licensed pharmacies can use to compound medications for individual patients.
The meeting was open to the public. Nominators presented supporting data, independent experts evaluated the evidence, and the committee voted on each substance for a specific proposed use. This was the first formal, public, evidence-based scientific review most of these peptides have received. (FDA.gov, Docket No. FDA-2025-N-6895)
Which Peptides Were Recommended for 503A Compounding?
The committee recommended six of the seven peptides under review for addition to the 503A Compounding Bulks List. Each was reviewed for a specific proposed use, and each recommendation is non-binding.
Recommended on July 23:
BPC-157 — A synthetic peptide based on a sequence found in gastric juice, studied for gastrointestinal and tissue repair. Reviewed for ulcerative colitis. Recommended 8-6, with one abstention.
KPV — A short tripeptide fragment of the alpha-MSH hormone, studied for anti-inflammatory and wound-healing uses. Reviewed for wound healing and inflammatory conditions. Recommended 8-6, with one abstention.
TB-500 — A synthetic fragment of the protein thymosin beta-4, studied for wound healing and tissue repair. Reviewed for wound healing. Recommended 8-6, with one abstention.
MOTS-c — A mitochondrial-derived peptide, studied for metabolic and bone health. Reviewed for obesity and osteoporosis. Recommended 7-5, with two abstentions.
Recommended on July 24:
Epitalon — A synthetic tetrapeptide, studied for sleep and aging-related outcomes. Reviewed for insomnia. Recommended 7-4.
Semax — A synthetic peptide related to a fragment of ACTH, used in some countries for cognitive and neurological conditions. Reviewed for cerebral ischemia, migraine, and trigeminal neuralgia. Recommended 8-5.
Not recommended:
The committee voted against recommending Emideltide (DSIP), a peptide studied for sleep that the FDA reviewed for opioid withdrawal, chronic insomnia, and narcolepsy. It failed on a 6-7 vote.
For organizations in longevity, hormone health, and performance medicine, several of these are directly relevant to programs patients are already asking about.
A second PCAC meeting is scheduled before February 2027 to review five additional peptides:
GHK-Cu
Cathelicidin LL-37
Dihexa Acetate
PEG-MGF
Melanotan II
What Does a PCAC Recommendation Actually Mean?
This is the most important point to understand about the six recommendations.
PCAC recommendations are non-binding. The committee evaluates the evidence and makes a recommendation to the FDA. The FDA then decides whether to act on it. A positive recommendation does not restore compounding access. It does not make a peptide approved to compound. It is one step in a longer process.
Compounding pharmacies cannot legally prepare these peptides until the FDA completes formal rulemaking. That process includes publishing a Notice of Proposed Rulemaking, opening a public comment period, and issuing a final rule.
What Happens After a PCAC Recommendation?
The July 23-24 meeting is a milestone, not a finish line. Here is what the process looks like from here:
PCAC issues recommendations for each peptide (non-binding). This step is now complete for the seven peptides reviewed.
FDA reviews the recommendations and decides whether to accept, modify, or reject them, and then, if appropriate, initiate rulemaking.
FDA publishes a Notice of Proposed Rulemaking.
Public comment period opens.
FDA issues a final rule adding substances to the 503A Bulks List.
Compounding would be legally permitted under Category 1.
Formal Rulemaking Does Not Mean FDA-Approval
Even after formal rulemaking is complete and a peptide reaches Category 1 status, it is still not FDA-approved. Category 1 is an interim enforcement position, not a drug approval. It means the FDA does not intend to take enforcement action against 503A pharmacies compounding that substance for individual patients, provided all applicable conditions are met, including:
A valid patient-specific prescription
A licensed 503A pharmacy in the dispensing state
USP <797> compliance
FDA-registered, prescription-grade API sourcing
Category 1 status also does not preempt or supersede state law. Some states have issued independent prohibitions on prescribing, dispensing, or compounding non-FDA-approved peptides that apply regardless of the federal enforcement posture. Organizations must confirm state compliance independently before initiating any compounding activity.
What Should Your Organization Do Now?
The July meeting signals the direction. The time between now and formal rulemaking is when preparation pays off.
Audit your pharmacy partnerships. Confirm third-party testing, FDA-registered prescription-grade API sourcing, 503A pharmacy state licensing coverage, and USP 797 compliance now, before patient volume accelerates.
Build your clinical protocols. Documented clinical rationale, patient-specific prescriptions, and informed consent processes take time to build correctly. Start now.
Map your state compliance gaps. Federal Category 1 status does not automatically satisfy state requirements. Some states have independent prohibitions on compounding, prescribing, or dispensing non-FDA approved peptides. Confirm your dispensing pharmacy network’s licensure and your prescriber network’s scope authority on a state-by-state basis before any formularies go live.
Monitor. Track regulatory updates as the recommended peptides enter in formal review.
Be Ready for Any Peptide Reclassification with OpenLoop
Peptide compounding regulations are still evolving, and the recommendation of six peptides could shift access quickly. OpenLoop provides white-label infrastructure support across key operational and regulatory components:
Access to compounded medications through licensed 503A pharmacy partners as regulatory authorization is established, in jurisdictions where compounding is lawfully permitted at the time of dispensing.
Medically reviewed, repeatable protocols
Licensed clinician network with credentialing and oversight across states where telehealth and applicable compounding access is permitted
Compliance-aligned infrastructure designed to adapt as federal and state regulations evolve
Patient support services available 24/7/365
You focus on your brand. OpenLoop handles the rest. Contact our team to get started.
This content is for general informational purposes only and does not constitute legal or medical advice. Regulatory classifications are subject to change. Consult qualified legal counsel and clinical advisors for guidance specific to your organization.
*This content is intended for general informational purposes only and should not be construed as legal advice. For guidance on your specific situation, please consult a licensed attorney.